Could weight loss drugs help prevent dementia?

(CN) — An analysis of nearly 1.7 million patient records suggests that semaglutide — the active ingredient in popular diabetes and weight loss medications like Ozempic and Wegovy — may significantly reduce the risk of developing dementia.

Researchers say in the study published Tuesday in the Journal of Alzheimer’s Disease that diabetes patients prescribed semaglutide showed lower rates of dementia compared to those using seven other anti-diabetic medications. The effects were most pronounced among women and older adults.

Dementia cases are projected to nearly doublefrom 6.7 million to 13 million by 2050.

“There is no cure or effective treatment for dementia, so this new study provides real-world evidence for its potential impact on preventing or slowing dementia development among at-high risk population,” Dr. Rong Xu, the lead researcher and a biomedical informatics professor at Case Western Reserve, said in a statement.

The research team analyzed three years of nationwide electronic health records using statistical methods designed to mimic randomized clinical trials. This approach allowed them to compare semaglutide not only with traditional diabetes medications but also with other drugs targeting the same biological pathway.

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists that reduce hunger and help regulate blood sugar in people with Type 2 diabetes. Ozempic is approved for managing diabetes and reducing heart disease risk, while Wegovy is approved specifically for weight management in adults with obesity.

Beyond these primary uses, the medication has demonstrated additional benefits including reducing heart disease risk and potentially protecting brain health.

The connection between diabetes medications and dementia prevention stems from shared risk factors between the conditions. Dementia results from damage to brain cells and their connections, leading to progressive memory and thinking difficulties.

Research from the National Institutes of Health suggests that nearly 45% of dementia cases could be prevented by addressing modifiable risk factors including obesity, Type 2 diabetes, cardiovascular disease, traumatic brain injury and stroke.

However, Xu emphasized caution in interpreting the results. While clinical trials testing semaglutide for Alzheimer’s prevention are underway and expected to complete their main phases in 2025, definitive conclusions can’t be drawn from observational data alone.

“Although their findings potentially support the idea that semaglutide could prevent dementia, the study’s limitations restrict the researchers from making firm causal conclusions,” Xu said.

“Our results indicate that research into semaglutide’s use for dementia prevention will need to be further investigated through randomized clinical trials,” Xu added.

Dementia currently causes more than 100,000 deaths each year in the United States, and those numbers could double by 2050 as baby boomers reach their 70s and 80s. This demographic shift highlights the need for treatments that can delay or prevent cognitive decline before symptoms appear.

Follow @JeremyYurow